[go: up one dir, main page]

PE20090812A1 - Derivados de aminoalquilazol como antagonistas de histamina-3 - Google Patents

Derivados de aminoalquilazol como antagonistas de histamina-3

Info

Publication number
PE20090812A1
PE20090812A1 PE2008001183A PE2008001183A PE20090812A1 PE 20090812 A1 PE20090812 A1 PE 20090812A1 PE 2008001183 A PE2008001183 A PE 2008001183A PE 2008001183 A PE2008001183 A PE 2008001183A PE 20090812 A1 PE20090812 A1 PE 20090812A1
Authority
PE
Peru
Prior art keywords
alkyl
aminoalkylazole
histamine
antagonists
compounds
Prior art date
Application number
PE2008001183A
Other languages
English (en)
Inventor
Jonathan Laird Gross
Albert Jean Robichaud
Alessandro Mazzacani
Marla Jean Williams
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20090812A1 publication Critical patent/PE20090812A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE AMINOALQUILAZOL DE FORMULA I, DONDE X ES NR13 O (CH2)p; Y ES NR14, O o S; R13 Y R14 SON CADA UNO H, o ALQUILO(C1-C6), ENTRE OTROS; R Y R' SON CADA UNO H, -(CR3R4)mNR1R2, HALO, ENTRE OTROS; R1 Y R2 SON CADA UNO H, ALQUILO(C1-C6), ENTRE OTROS; R3, R4, R7 Y R8 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C10), ENTRE OTROS; R5 Y R6 SON CADA UNO H, HALO, ALQUENILO(C2-C6), ENTRE OTROS; R9 ES NR11R12, ARILO(C6-C10), o HETROARILO DE 5-14 MIEMBROS, ENTRE OTROS; R11 Y R12 JUNTO AL ATOMO QUE SE ADHIEREN FORMAN SISTEMA DE ANILLO DE 9-11 MIEMBROS FUSIONADO BICICLICO OPCIONALMENTE SUSTITUIDO; m Y n SON CAD UNO DE 1-3; p ES 1 Ê 2. SON COMPUESTOS PREFERIDOS: 1-{4-[4-PIRROLIDIN-1-ILMETIL)-1,3-OXAZOL-2-IL]BENCIL}-1H-BENCIMIDAZOL, 1-{4-[4-PIPERIDIN-1-ILMETIL)-1,3-OXAZOL-2-IL]BENCIL}-1H-BENCIMIDAZOL, 1-{2-[4-(1H-BENCIMIDAZOL-1-ILMETIL)FENIL]-1,3-OXAZOL-4-IL}-N,N-DIMETILMETANAMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTOS DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DE HISTAMINA-3 SIENDO UTILES PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS TALES COMO DEMENCIA, TRASTORNO AMNESICO, ENFERMEDAD DE ALZHEIMER, ENTRE OTROS
PE2008001183A 2007-07-16 2008-07-15 Derivados de aminoalquilazol como antagonistas de histamina-3 PE20090812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95974107P 2007-07-16 2007-07-16

Publications (1)

Publication Number Publication Date
PE20090812A1 true PE20090812A1 (es) 2009-06-14

Family

ID=39708793

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001183A PE20090812A1 (es) 2007-07-16 2008-07-15 Derivados de aminoalquilazol como antagonistas de histamina-3

Country Status (10)

Country Link
US (1) US7803825B2 (es)
EP (1) EP2170875A1 (es)
JP (1) JP2010533725A (es)
AR (1) AR067549A1 (es)
CA (1) CA2693138A1 (es)
CL (1) CL2008002088A1 (es)
PA (1) PA8790101A1 (es)
PE (1) PE20090812A1 (es)
TW (1) TW200920356A (es)
WO (1) WO2009012252A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016609A1 (en) * 2008-07-15 2010-01-21 Wyeth Methods for the preparation of azole compounds
AU2010264422B2 (en) * 2009-06-26 2014-12-18 Sanofi Novel fumarate salts of a histamine H3 receptor antagonist
EA021047B1 (ru) * 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
US20120208827A1 (en) * 2009-10-27 2012-08-16 Glaxosmithkline Llc Benzimidazoles as fatty acid synthase inhibitors
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN103570705B (zh) * 2012-07-18 2017-01-25 中国医学科学院医药生物技术研究所 取代的n‑((1＇,3＇‑杂唑‑4＇‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途
MX2018011214A (es) 2016-03-15 2019-03-28 Bayer Cropscience Ag Sulfonamidas sustituidas para controlar plagas animales.
MX2023001758A (es) * 2020-08-11 2023-04-11 Univ Michigan State Potenciadores de proteasoma y usos de los mismos.
EP4467539A4 (en) * 2022-01-21 2025-11-05 Pasteur Institut Korea Oxazole-derived compound with antibacterial activity and its medical use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4168853A (en) * 1977-06-08 1979-09-25 Vetco, Inc. Shiftable ring gasket retainer for flanged connectors
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
CN1052224C (zh) 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO1998048800A1 (en) 1997-05-01 1998-11-05 Eli Lilly And Company Antithrombotic agents
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
ES2325477T3 (es) 2000-03-31 2009-09-07 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indoles sustituidos por fenilo como antagonistas del receptor de histamina h3.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
EP1603917B1 (en) 2003-03-14 2010-11-24 MediGene Ltd. Immunomodulating heterocyclic compounds
US7572784B2 (en) 2004-05-14 2009-08-11 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
BRPI0513777A (pt) 2004-07-26 2008-05-13 Lilly Co Eli composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
CA2577061C (en) 2004-08-23 2014-02-18 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008843A (es) 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
AU2007228778A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate AMPA receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
JP2010533725A (ja) 2010-10-28
US20090023707A1 (en) 2009-01-22
CA2693138A1 (en) 2009-01-22
EP2170875A1 (en) 2010-04-07
PA8790101A1 (es) 2009-02-09
AR067549A1 (es) 2009-10-14
CL2008002088A1 (es) 2008-09-05
US7803825B2 (en) 2010-09-28
TW200920356A (en) 2009-05-16
WO2009012252A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
PE20090812A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
AR059984A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
AR071284A1 (es) Compuestos heterociclicos con uniones puente y metodos para usarlos
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20191406A1 (es) N-[4-fluoro-5-[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
AR076460A1 (es) Antagonistas del receptor cxcr3
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR077147A1 (es) Compuestos biciclicos y triciclicos como inhibidores de kat ii
AR062937A1 (es) Compuestos que modulan el receptor cb2
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20090775A1 (es) Nuevos derivados de biarilo
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
PE20120063A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
CY1118623T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινων ως αναστολεις της bace
AR079260A1 (es) Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20081876A1 (es) Aminoamidas como antagonistas de orexina

Legal Events

Date Code Title Description
FD Application declared void or lapsed